Business Context and Reporting Period
Company: Novavax, Inc. (NVAX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2021
Event: Entry into a Material Definitive Agreement.
Key Financial Metrics
This filing is a qualitative report regarding a contractual agreement and does not contain quantitative financial data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreement Details
On October 26, 2021, Novavax entered into a Supply Agreement with Serum Institute of India Private Limited (SIIPL) and Serum Life Sciences Limited (SLS). Key terms include:
- Product: A vaccine derived from a coformulation of BV2373 antigen (including variants) and Matrix-M adjuvant.
- Relationship: SLS will supply the Product to Novavax for commercialization outside of SIIPL's exclusive licensed territory.
- Regulatory Responsibility: SIIPL is solely responsible for obtaining and maintaining necessary permits and regulatory approvals for manufacturing.
- Term: The agreement expires on the later of three years from the effective date or two years after the expiration/termination of the last firm purchase order.
- Termination: Either party may terminate for bankruptcy or uncured material breach.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a list of general risk factors. The primary contingency noted is the reliance on SIIPL to secure regulatory approvals for manufacturing. The full text of the Supply Agreement is referenced as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Investor Verification Checklist
- Verify the status of regulatory approvals held by SIIPL for the BV2373 antigen and Matrix-M adjuvant coformulation.
- Review the full Supply Agreement filed as an exhibit to the 2021 Form 10-K for specific pricing, volume commitments, and quality control standards.
- Confirm the scope of SIIPL's exclusive licensed territory to understand the geographic markets where Novavax will commercialize the supplied product.
- Monitor subsequent filings for any firm purchase orders issued under this agreement to determine the active term duration.